fig4

Figure 4. CD147 dependent effect of sEVs on angiogenic activities of HUVECs in vitro. (A) The uptake of PKH67-labeled HepG2-WT-sEVs by HUVECs was analyzed by immunofluorescent microscopy. Scale bar: 10 μm. Blue: DAPI; Red: Dil; Green: PKH67; (B, C, E, G): (B) HUVECs were treated with PBS, HepG2-WT-sEVs or HepG2-CD147(KD)-sEVs followed by cell proliferation assay (treatment time: 24 h); (C) wound healing assay (treatment time: 48 h); (E) transwell assay (treatment time: 24 h); (G) tube formation assay (treatment time: 6 h). Original magnification of image: × 40; (D, F, H) Quantification of wound closure as shown in (C) (D), the number of invaded cells in (E) (F), and the number of branch points in (G) (H). *: P < 0.05; ***: P < 0.001; ****: P < 0.0001; EVs: extracellular vesicles; HUVECs: human umbilical vein endothelial cells; PBS: phosphate‐buffered saline.